Form 4: Climb Bio Director Judith Dunn Receives Stock Options

Director Judith Dunn was granted 40,000 stock options in Climb Bio, Inc. with an exercise price of $10.55.

Summary

• Judith Dunn, a Director at Climb Bio, Inc., was granted 40,000 stock options on June 5, 2026.
• The options have an exercise price of $10.55 per share.
• The options are set to expire on June 4, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral in terms of immediate market impact.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• Potential future dilution of existing shareholders upon the exercise of these options.

Risks

• Market price volatility could impact the value of the options and the incentive structure for the director.

Future Outlook

The options vest on the earlier of June 5, 2027, or the day before the next annual meeting of stockholders, contingent upon continued service.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practice to ensure leadership remains focused on long-term growth and shareholder alignment.

Comparison to Industry Standards

• The grant of stock options to non-employee directors is consistent with standard compensation practices for publicly traded biotechnology companies.

Corporate Governance

Stakeholder Impact

• Shareholders may experience minor dilution if options are exercised in the future.

Next Steps

• Vesting of options on June 5, 2027, or the date of the next annual meeting.

Key Dates

Keywords

Climb Bio, CLYM, Form 4, Insider Trading, Stock Options, Director Compensation